Zealand Pharma A/S (ZEAL.CO)

DKK 802.5

(0.44%)

Net Income Summary of Zealand Pharma A/S

  • Zealand Pharma A/S's latest annual net income in 2023 was -703.73 Million DKK , up 27.12% from previous year.
  • Zealand Pharma A/S's latest quarterly net income in 2024 Q2 was -292.75 Million DKK , down -28.04% from previous quarter.
  • Zealand Pharma A/S reported an annual net income of -965.61 Million DKK in 2022, up 5.16% from previous year.
  • Zealand Pharma A/S reported an annual net income of -1.01 Billion DKK in 2021, down -20.24% from previous year.
  • Zealand Pharma A/S reported a quarterly net income of -228.64 Million DKK for 2024 Q1, up 13.64% from previous quarter.
  • Zealand Pharma A/S reported a quarterly net income of -264.75 Million DKK for 2023 Q4, down -457.07% from previous quarter.

Annual Net Income Chart of Zealand Pharma A/S (2023 - 2007)

Historical Annual Net Income of Zealand Pharma A/S (2023 - 2007)

Year Net Income Net Income Growth
2023 -703.73 Million DKK 27.12%
2022 -965.61 Million DKK 5.16%
2021 -1.01 Billion DKK -20.24%
2020 -846.72 Million DKK -48.15%
2019 -571.54 Million DKK -198.32%
2018 581.28 Million DKK 313.49%
2017 -272.27 Million DKK -76.9%
2016 -153.91 Million DKK -35.06%
2015 -113.95 Million DKK -75.35%
2014 -64.99 Million DKK 64.63%
2013 -183.75 Million DKK -605.22%
2012 36.37 Million DKK 433.86%
2011 6.81 Million DKK 106.51%
2010 -104.63 Million DKK -30.75%
2009 -80.02 Million DKK -137.25%
2008 -33.73 Million DKK 38.67%
2007 -55 Million DKK 0.0%

Peer Net Income Comparison of Zealand Pharma A/S

Name Net Income Net Income Difference
ALK-Abelló A/S 486 Million DKK 244.802%
Bavarian Nordic A/S 1.47 Billion DKK 147.705%
Genmab A/S 4.35 Billion DKK 116.17%
Gubra A/S -44.52 Million DKK -1480.584%
Novo Nordisk A/S 83.68 Billion DKK 100.841%
Orphazyme A/S -26.04 Million DKK -2601.701%
Pharma Equity Group A/S -24.6 Million DKK -2759.681%